Dr. Bible on Impact of Lenvatinib on Treatment Landscape of DTC

Keith C. Bible, MD, PhD
Published: Friday, Feb 19, 2016



Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer (DTC).

It is a plus to have another agent, such as lenvatinib, in this space as sorafenib demonstrates more modest activity in patients. Lenvatinib also elicits higher response rates in patients versus sorafenib, Bible explains. In patients with aggressive symptomatic disease, lenvatinib is a more cytoreductive approach that can help improve symptoms.

The approval of lenvatinib gives clinicians the opportunity to provide another therapy option to patients with DTC, Bible says.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium



Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer (DTC).

It is a plus to have another agent, such as lenvatinib, in this space as sorafenib demonstrates more modest activity in patients. Lenvatinib also elicits higher response rates in patients versus sorafenib, Bible explains. In patients with aggressive symptomatic disease, lenvatinib is a more cytoreductive approach that can help improve symptoms.

The approval of lenvatinib gives clinicians the opportunity to provide another therapy option to patients with DTC, Bible says.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x